 |
|
|
|
|
|
|
|
|
|
|
|
1 to 11 of 11 results |
|
 |
|
|
|
|
|
 |
|
|
|
|
Fisher A. on PAPER: Davis AA. et al., 2010, The paper by Davis et al. adds further support to the major and pivotal role of the M1... 30 Mar 2010.
|
|
|
 |
|
|
Fisher A. on PAPER: Kim M. et al., 2009, Recommendation Only. 29 Jul 2009.
|
|
|
|
|
|
Fisher A. on NEWS: New Kid on the Block: Nicotinic Receptor Sensitive to Aβ, This is a very interesting paper. It would be very important to know whether this receptor also... 4 Feb 2009.
|
|
|
|
|
|
Fisher A. on NEWS: TBPB or Not to Be—The Latest on Muscarinic Receptor Agonists, The difficulty in developing drugs for specific subtypes of some neurotransmitter receptors is... 8 Oct 2008.
|
|
|
|
|
|
Fisher A. on NEWS: Cholinergic Transmission and Aβ: Boosting M1 Receptors Treats Model, Reply by Abraham Fisher to Takaomi Saido
In reply to Takaomi Saido’s questions: The... 9 Mar 2006.
|
|
|
|
|
|
Fisher A. on NEWS: Special Delivery: NGF Trial Puts Growth Factor Where It’s Needed, Conner et al. (2005) show in this elegant paper that the basal forebrain cholinergic system... 28 Apr 2005.
|
|
|
|
|
|
Fisher A. on NEWS: α-Secretase Returns to Center Stage, Recommendation Only. 7 Jun 2004.
|
|
|
|
|
|
Fisher A. on PAPER: Perry EK. et al., 2003, Recommendation Only. 28 Jan 2004.
|
|
|
|
|
|
Fisher A. on PAPER: Nitsch RM. et al., 2000, Recommendation Only. 12 Aug 2003.
|
|
|
|
|
|
Fisher A. on PAPER: Volpicelli-Daley LA. et al., 2003, The authors report that acetylcholinesterase (AChE)-deficient mice have markedly decreased... 19 Jun 2003.
|
|
|
|
|
|
Fisher A. on NEWS: Lithium Hinders Aβ Generation, Buffing Up GSK as Drug Target, Phiel et al. (2003) show that Lithium (Li), an inhibitor of GSK3β and GSK3α, can decrease Aβ via... 3 Jun 2003.
|
|
|
|
|
|
|
1 to 11 of 11 results |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
The ALS Forum is a web-based collaborative effort to bring together valuable ALS-related resources for use by researchers worldwide in both academia and industry-based settings.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Should the FDA be allowed to use data from overseas clinical trials? |
|
|
|
|
|
|
|
|
|
|
|
Absolutely, we are running out of viable subjects in the U.S. |
|
|
|
|
|
|
 9 |
|
|
|
|
|
|
|
|
|
|
|
Yes, so long as the data is reliable |
|
|
|
|
|
|
31 |
|
|
|
|
|
|
|
|
|
|
|
No, the trials are not as rigorous |
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
|
|
|
No, the data should be repeated in the U.S. |
|
|
|
|
|
|
5 |
|
|
|
|
|
|
|
|
|
|
|
No, the drug sponsors are just trying to cut corners |
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
|
|
|
Responses: 51 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
Archived Polls |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
 Antibodies
Cell Lines
Collaborators
Papers
Research Participants
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Home
See our latest Webinar: 
